Jonathan Schechter insider trades

Open-market stock purchases and sales by Jonathan Schechter, Director at PharmaCyte Biotech, Inc, from SEC Form 4 filings since Dec 13, 2018.

Track record: 63% of 8 scored buys are up 5% or more since purchase, averaging +52%.

Recent trades

DateStockTradeValue
Mar 31, 2026PMCB PharmaCyte Biotech, IncBought (not open market)—
Jan 7, 2026PMCB PharmaCyte Biotech, IncBought$16.9K
Jan 6, 2026PMCB PharmaCyte Biotech, IncBought$15.8K
Jan 5, 2026PMCB PharmaCyte Biotech, IncBought$15.6K
Dec 12, 2025PMCB PharmaCyte Biotech, IncSold (not open market)$68.8K
Dec 12, 2025PMCB PharmaCyte Biotech, IncBought (not open market)—
Nov 14, 2025OBLG Oblong, IncBought$19.1K

Companies traded

  • PMCB PharmaCyte Biotech, Inc: 3 buys, last Mar 31, 2026
  • OBLG Oblong, Inc: 3 buys, last Nov 14, 2025
  • TAOX TAO Synergies Inc: other filings, last Aug 6, 2025
  • SNPX Synaptogenix, Inc: 1 sale, last Apr 3, 2025
  • NTRP Neurotrope, Inc: 4 buys, last Dec 1, 2020

Get free alerts when Jonathan Schechter files a new trade →